バイコアに関するコメント

Vicor's declining ROCE and modest 24% stock return over five years hint at limited multi-bagger potential. Despite shrinking returns, the company's reinvestment is somewhat encouraging but fails to counteract negative trends.

The downgrade in Vicor's earnings and revenue estimates suggests potential business headwinds. The market may become more wary of the business given the scope of the downgrades.

Analysts' sentiment dips following latest results, with significant cuts to revenue estimates and a slight decrease in EPS. Price targets also reduced, indicating increased pessimism about the business's intrinsic value.

Vicor's high P/E ratio, seen as unsustainable, is due to investor expectations of continued market outperformance. However, with forecasted growth lower than the market, current prices may be unreasonable without significant conditions improvement.

Analyses reveal skepticism in Vicor's potential due to unimpressive ROCE and stagnant sales, even after capital reinvestment. The uninspiring trends suggest investors may find better opportunities elsewhere.

Insider shares sold at a price much higher than the current one might indicate a lack of confidence in the current price level. Sustained high insider ownership could suggest alignment between management and shareholder interests.

Analysts bearish on Vicor's prospects post latest results, leading to a marked down revenue and slashed EPS estimates. Its projected revenue growth through 2024 is anticipated lower than industry average.

Needham has downgraded due to unsatisfactory booking and backlog data, cautious management tone, and intensified competition eating into Vicor's business. They predict the stock to be range-bound for the coming year and have lowered Vicor's 2024/2025 estimates.